-
1
-
-
77951586447
-
Strategies and challenges for the next generation of therapeutic antibodies
-
PMID:20414207
-
Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 345-352
-
-
Beck, A.1
Wurch, T.2
Bailly, C.3
Corvaia, N.4
-
2
-
-
79955666020
-
Introduction to current and future protein therapeutics: A protein engineering perspective
-
PMID:21371474
-
Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011; 317:1261-9; PMID:21371474; http://dx.doi.org/10.1016/j.yexcr.2011.02.013
-
(2011)
Exp Cell Res
, vol.317
, pp. 1261-1269
-
-
Carter, P.J.1
-
3
-
-
77951529848
-
Therapeutic antibodies for autoimmunity and inflammation
-
PMID:20414204
-
Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
-
(2010)
Nat Rev Immunol
, vol.10
, pp. 301-316
-
-
Chan, A.C.1
Carter, P.J.2
-
4
-
-
34248382009
-
Bispecific antibodies: Molecules that enable novel therapeutic strategies
-
PMID:17496428
-
Fischer N, Léger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx.doi.org/10.1159/000101046
-
(2007)
Pathobiology
, vol.74
, pp. 3-14
-
-
Fischer, N.1
Léger, O.2
-
5
-
-
84856371864
-
Enhanced HIV-1 neutralization by antibody heteroligation
-
PMID:22219363
-
Mouquet H, Warncke M, Scheid JF, Seaman MS, Nussenzweig MC. Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A 2012; 109:875-80; PMID:22219363; http://dx.doi.org/10.1073/pnas.1120059109
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, pp. 875-880
-
-
Mouquet, H.1
Warncke, M.2
Scheid, J.F.3
Seaman, M.S.4
Nussenzweig, M.C.5
-
6
-
-
79957452852
-
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo
-
PMID:21613622
-
Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 2011; 3:84ra43; PMID:21613622; http://dx.doi.org/10.1126/ scitranslmed.3002254
-
(2011)
Sci Transl Med
, vol.3
-
-
Atwal, J.K.1
Chen, Y.2
Chiu, C.3
Mortensen, D.L.4
Meilandt, W.J.5
Liu, Y.6
-
7
-
-
79959312575
-
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
-
PMID:21576633
-
Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
-
(2011)
J Clin Oncol
, vol.29
, pp. 2493-2498
-
-
Topp, M.S.1
Kufer, P.2
Gökbuget, N.3
Goebeler, M.4
Klinger, M.5
Neumann, S.6
-
8
-
-
77951596808
-
Catumaxomab: Clinical development and future directions
-
PMID:20190561
-
Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/ mabs.2.2.11221
-
(2010)
MAbs
, vol.2
, pp. 129-136
-
-
Linke, R.1
Klein, A.2
Seimetz, D.3
-
9
-
-
80155150449
-
Buy buy bispecific antibodies
-
PMID:22037028
-
Holmes D. Buy buy bispecific antibodies. Nat Rev Drug Discov 2011; 10:798-800; PMID:22037028; http://dx.doi.org/10.1038/nrd3581
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 798-800
-
-
Holmes, D.1
-
10
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
-
PMID:22248472
-
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0820
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 582-593
-
-
McDonagh, C.F.1
Huhalov, A.2
Harms, B.D.3
Adams, S.4
Paragas, V.5
Oyama, S.6
-
11
-
-
78651091039
-
Chemical generation of bispecific antibodies
-
PMID:21149738
-
Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 22611-22616
-
-
Doppalapudi, V.R.1
Huang, J.2
Liu, D.3
Jin, P.4
Liu, B.5
Li, L.6
-
12
-
-
77955976111
-
Stability engineering of scFvs for the development of bispecific and multivalent antibodies
-
PMID:20457695
-
Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
-
(2010)
Protein Eng des Sel
, vol.23
, pp. 549-557
-
-
Miller, B.R.1
Demarest, S.J.2
Lugovskoy, A.3
Huang, F.4
Wu, X.5
Snyder, W.B.6
-
13
-
-
50249132634
-
Antibody therapeutics, antibody engineering, and the merits of protein stability
-
PMID:18729019
-
Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675-87; PMID:18729019
-
(2008)
Curr Opin Drug Discov Devel
, vol.11
, pp. 675-687
-
-
Demarest, S.J.1
Glaser, S.M.2
-
14
-
-
79955658810
-
Rational engineering of antibody therapeutics targeting multiple oncogene pathways
-
PMID:21393992
-
Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 2011; 3:299-309; PMID:21393992; http://dx.doi.org/10.4161/mabs.3.3.15299
-
(2011)
MAbs
, vol.3
, pp. 299-309
-
-
Fitzgerald, J.1
Lugovskoy, A.2
-
15
-
-
79957683054
-
Bispecific digoxigenin-binding antibodies for targeted payload delivery
-
PMID:21536919
-
Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A 2011; 108:8194-9; PMID:21536919; http://dx.doi.org/10.1073/pnas. 1018565108
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 8194-8199
-
-
Metz, S.1
Haas, A.K.2
Daub, K.3
Croasdale, R.4
Stracke, J.5
Lau, W.6
-
16
-
-
79955548494
-
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains
-
PMID:21300827
-
Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55:2369-78; PMID:21300827; http://dx.doi.org/10.1128/ AAC.00215-10
-
(2011)
Antimicrob Agents Chemother
, vol.55
, pp. 2369-2378
-
-
Schanzer, J.1
Jekle, A.2
Nezu, J.3
Lochner, A.4
Croasdale, R.5
Dioszegi, M.6
-
17
-
-
80052580966
-
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design
-
PMID:21814039
-
Digiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs 2011; 3:487-94; PMID:21814039; http://dx.doi.org/10.4161/mabs.3.5.16326
-
(2011)
MAbs
, vol.3
, pp. 487-494
-
-
Digiammarino, E.L.1
Harlan, J.E.2
Walter, K.A.3
Ladror, U.S.4
Edalji, R.P.5
Hutchins, C.W.6
-
18
-
-
35948977323
-
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
-
PMID:17934452
-
Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
-
(2007)
Nat Biotechnol
, vol.25
, pp. 1290-1297
-
-
Wu, C.1
Ying, H.2
Grinnell, C.3
Bryant, S.4
Miller, R.5
Clabbers, A.6
-
19
-
-
39449129555
-
Construction of optimized bispecific antibodies for selective activation of the death receptor CD95
-
PMID:18281499
-
Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG, Jung G. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008; 68:1221-7; PMID:18281499; http://dx.doi.org/10.1158/0008-5472.CAN-07-6175
-
(2008)
Cancer Res
, vol.68
, pp. 1221-1227
-
-
Herrmann, T.1
Grosse-Hovest, L.2
Otz, T.3
Krammer, P.H.4
Rammensee, H.G.5
Jung, G.6
-
20
-
-
79960650492
-
A novel redox method for rapid production of functional bispecific antibodies for use in early pilot studies
-
PMID:21811628
-
Carlring J, De Leenheer E, Heath AW. A novel redox method for rapid production of functional bispecific antibodies for use in early pilot studies. PLoS One 2011; 6:e22533; PMID:21811628; http://dx.doi.org/10.1371/journal.pone. 0022533
-
(2011)
PLoS One
, vol.6
-
-
Carlring, J.1
De Leenheer, E.2
Heath, A.W.3
-
21
-
-
0026035394
-
Absence of preferential homologous H/L chain association in hybrid hybridomas
-
PMID:1899099
-
De Lau WB, Heije K, Neefjes JJ, Oosterwegel M, Rozemuller E, Bast BJ. Absence of preferential homologous H/L chain association in hybrid hybridomas. J Immunol 1991; 146:906-14; PMID:1899099
-
(1991)
J Immunol
, vol.146
, pp. 906-914
-
-
De Lau, W.B.1
Heije, K.2
Neefjes, J.J.3
Oosterwegel, M.4
Rozemuller, E.5
Bast, B.J.6
-
22
-
-
0024350251
-
Hybrid antibodies in cancer diagnosis and therapy
-
PMID:2693537
-
Ménard S, Canevari S, Colnaghi MI. Hybrid antibodies in cancer diagnosis and therapy. Int J Biol Markers 1989; 4:131-4; PMID:2693537
-
(1989)
Int J Biol Markers
, vol.4
, pp. 131-134
-
-
Ménard, S.1
Canevari, S.2
Colnaghi, M.I.3
-
23
-
-
0028227751
-
Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
-
PMID:8171337
-
Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264:833-5; PMID:8171337; http://dx.doi.org/10.1126/science. 8171337
-
(1994)
Science
, vol.264
, pp. 833-835
-
-
Renner, C.1
Jung, W.2
Sahin, U.3
Denfeld, R.4
Pohl, C.5
Trümper, L.6
-
24
-
-
0029063312
-
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
-
PMID:7602098
-
Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
-
(1995)
J Immunol
, vol.155
, pp. 219-225
-
-
Lindhofer, H.1
Mocikat, R.2
Steipe, B.3
Thierfelder, S.4
-
25
-
-
0033178740
-
Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing
-
PMID:10415020
-
Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246-52; PMID:10415020
-
(1999)
J Immunol
, vol.163
, pp. 1246-1252
-
-
Zeidler, R.1
Reisbach, G.2
Wollenberg, B.3
Lang, S.4
Chaubal, S.5
Schmitt, B.6
-
26
-
-
77953665930
-
Structural and functional characterization of the trifunctional antibody catumaxomab
-
PMID:20418662
-
Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs. 2.3.11791
-
(2010)
MAbs
, vol.2
, pp. 309-319
-
-
Chelius, D.1
Ruf, P.2
Gruber, P.3
Plöscher, M.4
Liedtke, R.5
Gansberger, E.6
-
27
-
-
0035251453
-
Bispecific human IgG by design
-
PMID:11223065
-
Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
-
(2001)
J Immunol Methods
, vol.248
, pp. 7-15
-
-
Carter, P.1
-
28
-
-
0031876578
-
An efficient route to human bispecific IgG
-
PMID:9661204
-
Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
-
(1998)
Nat Biotechnol
, vol.16
, pp. 677-681
-
-
Merchant, A.M.1
Zhu, Z.2
Yuan, J.Q.3
Goddard, A.4
Adams, C.W.5
Presta, L.G.6
-
29
-
-
0030909820
-
Remodeling domain interfaces to enhance heterodimer formation
-
PMID:9098887
-
Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
-
(1997)
Protein Sci
, vol.6
, pp. 781-788
-
-
Zhu, Z.1
Presta, L.G.2
Zapata, G.3
Carter, P.4
-
30
-
-
0029946383
-
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization
-
PMID:8844834
-
Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
-
(1996)
Protein Eng
, vol.9
, pp. 617-621
-
-
Ridgway, J.B.1
Presta, L.G.2
Carter, P.3
-
31
-
-
0031552589
-
Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library
-
PMID:9231898
-
Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
-
(1997)
J Mol Biol
, vol.270
, pp. 26-35
-
-
Atwell, S.1
Ridgway, J.B.2
Wells, J.A.3
Carter, P.4
-
32
-
-
49249100382
-
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
-
PMID:18519697
-
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-8; PMID:18519697; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960
-
(2008)
Cancer Res
, vol.68
, pp. 4360-4368
-
-
Jin, H.1
Yang, R.2
Zheng, Z.3
Romero, M.4
Ross, J.5
Bou-Reslan, H.6
-
33
-
-
33750683969
-
A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo
-
PMID:17062691
-
Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-52; PMID:17062691; http://dx.doi.org/10. 1158/1078-0432.CCR-05-1418
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6144-6152
-
-
Martens, T.1
Schmidt, N.O.2
Eckerich, C.3
Fillbrandt, R.4
Merchant, M.5
Schwall, R.6
-
34
-
-
80555135913
-
Role of MetMAb (OA-5D5) in c-MET active lung malignancies
-
PMID:22047509
-
Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011; 11:1655-62; PMID:22047509; http://dx.doi.org/10.1517/14712598.2011.626762
-
(2011)
Expert Opin Biol Ther
, vol.11
, pp. 1655-1662
-
-
Surati, M.1
Patel, P.2
Peterson, A.3
Salgia, R.4
-
35
-
-
84869753306
-
Methods for producing polypeptides by regulating polypeptide association
-
WO2006106905
-
Igawa T, Tsunoda H. Methods for producing polypeptides by regulating polypeptide association. WO2006106905. 2006
-
(2006)
-
-
Igawa, T.1
Tsunoda, H.2
-
36
-
-
77953485268
-
Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG
-
PMID:20400508
-
Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382. 22123055
-
(2010)
J Biol Chem
, vol.285
, pp. 19637-19646
-
-
Gunasekaran, K.1
Pentony, M.2
Shen, M.3
Garrett, L.4
Forte, C.5
Woodward, A.6
-
37
-
-
81255210896
-
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
-
PMID:22123055
-
Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-57.; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
-
(2011)
MAbs
, vol.3
, pp. 546-557
-
-
Moore, G.L.1
Bautista, C.2
Pong, E.3
Nguyen, D.H.4
Jacinto, J.5
Eivazi, A.6
-
38
-
-
77954628740
-
SEEDbodies: Fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
-
PMID:20299542
-
Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
-
(2010)
Protein Eng des Sel
, vol.23
, pp. 195-202
-
-
Davis, J.H.1
Aperlo, C.2
Li, Y.3
Kurosawa, E.4
Lan, Y.5
Lo, K.M.6
-
39
-
-
79955440692
-
Therapeutic assessment of SEED: A new engineered antibody platform designed to generate mono- And bispecific antibodies
-
PMID:21498564
-
Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 2011; 24:447-54; PMID:21498564; http://dx.doi.org/10.1093/protein/gzq123
-
(2011)
Protein Eng des Sel
, vol.24
, pp. 447-454
-
-
Muda, M.1
Gross, A.W.2
Dawson, J.P.3
He, C.4
Kurosawa, E.5
Schweickhardt, R.6
-
40
-
-
0027442660
-
Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli
-
N Y PMID:7764189
-
Pack P, Kujau M, Schroeckh V, Knüpfer U, Wenderoth R, Riesenberg D, et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y) 1993; 11:1271-7; PMID:7764189
-
(1993)
Biotechnology
, vol.11
, pp. 1271-1277
-
-
Pack, P.1
Kujau, M.2
Schroeckh, V.3
Knüpfer, U.4
Wenderoth, R.5
Riesenberg, D.6
-
41
-
-
0026567963
-
Formation of a bispecific antibody by the use of leucine zippers
-
PMID:1531669
-
Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148:1547-53; PMID:1531669
-
(1992)
J Immunol
, vol.148
, pp. 1547-1553
-
-
Kostelny, S.A.1
Cole, M.S.2
Tso, J.Y.3
-
42
-
-
84869815266
-
Coiled coil and/or tether containing protein complexes and uses thereof
-
WO2011034605
-
Christensen EH, Eaton DL, Vendel AC, Wranik B. Coiled coil and/or tether containing protein complexes and uses thereof. WO2011034605. 2011
-
(2011)
-
-
Christensen, E.H.1
Eaton, D.L.2
Vendel, A.C.3
Wranik, B.4
-
43
-
-
84869815734
-
Antibody producing non-mammals
-
WO2009157771
-
Houtzager E, Pinto RD, Logtenberg T, Throsby M, Kramer RA, De Kruif CA. Antibody producing non-mammals. WO2009157771. 2009
-
(2009)
-
-
Houtzager, E.1
Pinto, R.D.2
Logtenberg, T.3
Throsby, M.4
Kramer, R.A.5
De Kruif, C.A.6
-
44
-
-
84869815733
-
Common light chain mouse
-
WO2011097603
-
McWhirter J, Macdonald L, Stevens S, Davis S, Buckler DR, Murphy AJ. Common light chain mouse. WO2011097603. 2011
-
(2011)
-
-
McWhirter, J.1
Macdonald, L.2
Stevens, S.3
Davis, S.4
Buckler, D.R.5
Murphy, A.J.6
-
45
-
-
77954225154
-
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling
-
PMID:20444694
-
Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M110.113910
-
(2010)
J Biol Chem
, vol.285
, pp. 20850-20859
-
-
Jackman, J.1
Chen, Y.2
Huang, A.3
Moffat, B.4
Scheer, J.M.5
Leong, S.R.6
-
46
-
-
77954996067
-
VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist singlechain diabody
-
PMID:20576629
-
Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist singlechain diabody. Protein Eng Des Sel 2010; 23:667-77; PMID:20576629; http://dx.doi.org/10.1093/protein/ gzq034
-
(2010)
Protein Eng des Sel
, vol.23
, pp. 667-677
-
-
Igawa, T.1
Tsunoda, H.2
Kikuchi, Y.3
Yoshida, M.4
Tanaka, M.5
Koga, A.6
-
47
-
-
79960592856
-
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
-
PMID:21690412
-
Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, pp. 11187-11192
-
-
Schaefer, W.1
Regula, J.T.2
Bähner, M.3
Schanzer, J.4
Croasdale, R.5
Dürr, H.6
-
48
-
-
84891923917
-
Crossing over to bispecificity
-
Cain C. Crossing over to bispecificity. SciBX 2011; 4:1-4
-
(2011)
SciBX
, vol.4
, pp. 1-4
-
-
Cain, C.1
-
49
-
-
80053463397
-
A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis
-
PMID:21851472
-
Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 2011; 18:598-607; PMID:21851472; http://dx.doi.org/10.1111/j. 1549-8719.2011.00120.x
-
(2011)
Microcirculation
, vol.18
, pp. 598-607
-
-
Rennel, E.S.1
Regula, J.T.2
Harper, S.J.3
Thomas, M.4
Klein, C.5
Bates, D.O.6
-
50
-
-
84869815735
-
Readily isolated bispecific antibodies with native immunoglobulin format
-
WO2010151792
-
Davis S, Smith E, Macdonald D, Olson KL. Readily isolated bispecific antibodies with native immunoglobulin format. WO2010151792. 2011
-
(2011)
-
-
Davis, S.1
Smith, E.2
Macdonald, D.3
Olson, K.L.4
-
51
-
-
84869815268
-
Antibody Modification Method for Purifying Bispecific Antibody
-
WO2007114325
-
Igawa T, Tsunoda H. Antibody Modification Method For Purifying Bispecific Antibody. WO2007114325. 2011
-
(2011)
-
-
Igawa, T.1
Tsunoda, H.2
-
52
-
-
79957439772
-
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target
-
PMID:21613623
-
Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3:84ra44; PMID:21613623; http://dx.doi.org/10.1126/ scitranslmed.3002230
-
(2011)
Sci Transl Med
, vol.3
-
-
Yu, Y.J.1
Zhang, Y.2
Kenrick, M.3
Hoyte, K.4
Luk, W.5
Lu, Y.6
-
53
-
-
73149121904
-
Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys
-
PMID:19850673
-
Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 2010; 38:84-91; PMID:19850673; http://dx.doi.org/10.1124/dmd.109.029751
-
(2010)
Drug Metab Dispos
, vol.38
, pp. 84-91
-
-
Stubenrauch, K.1
Wessels, U.2
Regula, J.T.3
Kettenberger, H.4
Schleypen, J.5
Kohnert, U.6
-
54
-
-
68449083226
-
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
-
PMID:19620983
-
Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553
-
(2009)
Nat Biotechnol
, vol.27
, pp. 767-771
-
-
Labrijn, A.F.1
Buijsse, A.O.2
Van Den Bremer, E.T.3
Verwilligen, A.Y.4
Bleeker, W.K.5
Thorpe, S.J.6
-
55
-
-
34548694517
-
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
-
PMID:17872445
-
van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603
-
(2007)
Science
, vol.317
, pp. 1554-1557
-
-
Van Der Neut Kolfschoten, M.1
Schuurman, J.2
Losen, M.3
Bleeker, W.K.4
Martínez-Martínez, P.5
Vermeulen, E.6
-
56
-
-
84871051316
-
Heterodimeric Antibody Fc-Containing Proteins and Methods for Production Thereof
-
WO2011131746
-
Labrijn AF, Meesters J, van den BremerE, Neijssen JJ, van Berkel P, de Goeij B, et al. Heterodimeric Antibody Fc-Containing Proteins And Methods For Production Thereof. WO2011131746. 2011
-
(2011)
-
-
Labrijn, A.F.1
Meesters, J.2
Van Den Bremer, E.3
Neijssen, J.J.4
Van Berkel, P.5
De Goeij, B.6
-
57
-
-
84862015979
-
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair
-
PMID:22543237
-
Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012. 04.020
-
(2012)
J Mol Biol
, vol.420
, pp. 204-219
-
-
Strop, P.1
Ho, W.H.2
Boustany, L.M.3
Abdiche, Y.N.4
Lindquist, K.C.5
Farias, S.E.6
-
58
-
-
80555156163
-
Smarter drugs: A focus on pan-specific monoclonal antibodies
-
PMID:22050338
-
Fagète S, Fischer N. Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs 2011; 25:357-64; PMID:22050338; http://dx.doi.org/10.2165/11594690-000000000-00000
-
(2011)
BioDrugs
, vol.25
, pp. 357-364
-
-
Fagète, S.1
Fischer, N.2
-
59
-
-
77956940247
-
Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis
-
PMID:20644170
-
Buatois V, Fagète S, Magistrelli G, Chatel L, Fischer N, Kosco-Vilbois MH, et al. Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis. J Immunol 2010; 185:2544-54; PMID:20644170; http://dx.doi.org/10.4049/jimmunol.1000182
-
(2010)
J Immunol
, vol.185
, pp. 2544-2554
-
-
Buatois, V.1
Fagète, S.2
Magistrelli, G.3
Chatel, L.4
Fischer, N.5
Kosco-Vilbois, M.H.6
-
60
-
-
33645819161
-
A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus
-
PMID:16581912
-
Alejo A, Ruiz-Argüello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A 2006; 103:5995-6000; PMID:16581912; http://dx.doi.org/10.1073/pnas.0510462103
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 5995-6000
-
-
Alejo, A.1
Ruiz-Argüello, M.B.2
Ho, Y.3
Smith, V.P.4
Saraiva, M.5
Alcami, A.6
-
61
-
-
84855478513
-
Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry
-
PMID:22041899
-
Fagète S, Rousseau F, Magistrelli G, Gueneau F, Ravn U, Kosco-Vilbois MH, et al. Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem 2012; 287:1458-67; PMID:22041899; http://dx.doi.org/10.1074/jbc. M111.253658
-
(2012)
J Biol Chem
, vol.287
, pp. 1458-1467
-
-
Fagète, S.1
Rousseau, F.2
Magistrelli, G.3
Gueneau, F.4
Ravn, U.5
Kosco-Vilbois, M.H.6
-
62
-
-
79955545620
-
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity
-
PMID:21526167
-
Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6:e17887; PMID:21526167; http://dx.doi.org/10.1371/journal.pone.0017887
-
(2011)
PLoS One
, vol.6
-
-
Bostrom, J.1
Haber, L.2
Koenig, P.3
Kelley, R.F.4
Fuh, G.5
-
63
-
-
62849095162
-
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
-
PMID:19299620
-
Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10. 1126/science.1165480
-
(2009)
Science
, vol.323
, pp. 1610-1614
-
-
Bostrom, J.1
Yu, S.F.2
Kan, D.3
Appleton, B.A.4
Lee, C.V.5
Billeci, K.6
-
64
-
-
64949153511
-
Improving antibody binding affinity and specificity for therapeutic development.
-
xiii. PMID:19252851
-
Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.]. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
-
(2009)
Methods Mol Biol
, vol.525
-
-
Bostrom, J.1
Lee, C.V.2
Haber, L.3
Fuh, G.4
-
65
-
-
80054765331
-
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
-
PMID:22014573
-
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
-
(2011)
Cancer Cell
, vol.20
, pp. 472-486
-
-
Schaefer, G.1
Haber, L.2
Crocker, L.M.3
Shia, S.4
Shao, L.5
Dowbenko, D.6
-
66
-
-
77954638589
-
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
-
PMID:20150180
-
Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289-97; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005
-
(2010)
Protein Eng des Sel
, vol.23
, pp. 289-297
-
-
Wozniak-Knopp, G.1
Bartl, S.2
Bauer, A.3
Mostageer, M.4
Woisetschläger, M.5
Antes, B.6
-
67
-
-
79952271693
-
Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth
-
PMID:21233403
-
Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17:1001-11; PMID:21233403; http://dx.doi.org/10.1158/1078-0432.CCR-10-2317
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1001-1011
-
-
Huang, H.1
Lai, J.Y.2
Do, J.3
Liu, D.4
Li, L.5
Del Rosario, J.6
|